Rossini Maurizio, Orsolini Giovanni, Viapiana Ombretta, Adami Silvano, Gatti Davide
Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy,
Endocrine. 2015 Aug;49(3):620-7. doi: 10.1007/s12020-014-0506-5. Epub 2015 Feb 4.
In glucocorticoid-induced osteoporosis (GIO), both bone formation and resorption are altered, however, with a relative prevalence of resorption, consistent with the positive results that have been reported with bisphosphonate treatment. Many studies have investigated the effect of bisphosphonates (BPs), a widely used class of anti-resorptive drugs, showing a positive effect on bone mineral density and fracture risk. Also in case of postmenopausal osteoporosis, the safety and cost-effectiveness profile of BPs in GIO appears good. Currently, the use of BPs is recommended at the earliest by all major scientific societies in postmenopausal women and men ≥50 years at high risk of fracture receiving glucocorticoid therapy. BPs are the most commonly used anti-osteoporotic agents and they remain the current standard of care for GIO.
在糖皮质激素诱导的骨质疏松症（GIO）中，骨形成和骨吸收均发生改变，但骨吸收相对更为普遍，这与双膦酸盐治疗所报告的阳性结果一致。许多研究调查了双膦酸盐（BPs）的作用，双膦酸盐是一类广泛使用的抗骨吸收药物，对骨矿物质密度和骨折风险显示出积极作用。同样，在绝经后骨质疏松症的情况下，双膦酸盐在GIO中的安全性和成本效益也表现良好。目前，所有主要科学学会均建议，对于接受糖皮质激素治疗且骨折风险高的绝经后女性和≥50岁男性，应尽早使用双膦酸盐。双膦酸盐是最常用的抗骨质疏松药物，仍是目前GIO的标准治疗方法。
